Neurogen's lead clinical development programs are in Parkinson's disease and Restless legs syndrome (RLS) with its dopamine partial agonist, aplindore. The partial agonist and controlled release properties of aplindore provide the potential for improved tolerability and dosing flexibility over existing therapeutics.